These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17136064)

  • 1. The bitterest pill.
    Nature; 2006 Nov; 444(7119):532-3. PubMed ID: 17136064
    [No Abstract]   [Full Text] [Related]  

  • 2. NXY-059 for the treatment of stroke.
    Savitz SI; Fisher M
    N Engl J Med; 2007 Nov; 357(21):2198; author reply 2198-9. PubMed ID: 18032772
    [No Abstract]   [Full Text] [Related]  

  • 3. Lay-offs follow suspension of clinical trials of protein.
    Verrall M
    Nature; 1994 Jul; 370(6484):6. PubMed ID: 8015607
    [No Abstract]   [Full Text] [Related]  

  • 4. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.
    Feuerstein GZ; Zaleska MM; Krams M; Wang X; Day M; Rutkowski JL; Finklestein SP; Pangalos MN; Poole M; Stiles GL; Ruffolo RR; Walsh FL
    J Cereb Blood Flow Metab; 2008 Jan; 28(1):217-9. PubMed ID: 17579658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NXY-059 for acute ischemic stroke.
    Koziol JA
    N Engl J Med; 2006 May; 354(19):2075-6; author reply 2075-6. PubMed ID: 16696147
    [No Abstract]   [Full Text] [Related]  

  • 6. The cost of bringing a radiopharmaceutical to the patient's bedside.
    Nunn AD
    J Nucl Med; 2007 Feb; 48(2):169. PubMed ID: 17268008
    [No Abstract]   [Full Text] [Related]  

  • 7. NXY-059. Centaur.
    Lapchak PA
    Curr Opin Investig Drugs; 2002 Dec; 3(12):1758-62. PubMed ID: 12528313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinued drugs in 2008: cardiovascular drugs.
    Zhang XS; Xiang BR
    Expert Opin Investig Drugs; 2009 Jul; 18(7):875-85. PubMed ID: 19548849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban, an oral, direct inhibitor of activated Factor Xa.
    Shantsila E; Lip GY
    Curr Opin Investig Drugs; 2008 Sep; 9(9):1020-33. PubMed ID: 18729009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development research: diabetes favored over cardiovascular disease?
    Suckling K
    Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
    [No Abstract]   [Full Text] [Related]  

  • 11. Corporate influence over planning and presentation of clinical trials: beauty and the beast.
    Fuchs FD
    Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):7-9. PubMed ID: 20014930
    [No Abstract]   [Full Text] [Related]  

  • 12. Deal watch: AbbVie invests in pioneering celiac disease therapy.
    Crunkhorn S
    Nat Rev Drug Discov; 2013 Jul; 12(7):497. PubMed ID: 23812262
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemoprevention clinical trials: it is time to turn success into progress.
    Brown PH
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
    Hutson TE
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAINT-I worked, but the neuroprotectant is not NXY-059.
    Proctor PH; Tamborello LP
    Stroke; 2007 Oct; 38(10):e109; author reply e110. PubMed ID: 17717310
    [No Abstract]   [Full Text] [Related]  

  • 16. Scope of preclinical testing versus quality control within experiments.
    O'Collins VE; Donnan GA; Macleod MR; Howells DW
    Stroke; 2009 Jul; 40(7):e497. PubMed ID: 19498189
    [No Abstract]   [Full Text] [Related]  

  • 17. [Economic or medical innovations: that is the question!].
    Freitag MH; Wohlgemuth WA
    Med Klin (Munich); 2006 Jul; 101(7):590-1; author reply 591-3. PubMed ID: 16897896
    [No Abstract]   [Full Text] [Related]  

  • 18. Is NXY-059 an advancement in the treatment of acute ischaemic stroke?
    Doggrell SA
    Expert Opin Pharmacother; 2006 May; 7(7):965-8. PubMed ID: 16634718
    [No Abstract]   [Full Text] [Related]  

  • 19. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
    Kelley RK; Venook AP
    J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
    [No Abstract]   [Full Text] [Related]  

  • 20. Can 'double blockbuster' strengthen Amgen's backbone?
    Sheridan C
    Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.